The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAutonomix Medical, Inc. (NASDAQ: AMIX) announced that its research abstract has been selected for a featured podium presentation at the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting. The research focuses on long-term pain mitigation in pancreatic cancer patients using the company's transvascular RF energy-based ablation technology. This precision nerve-targeted approach aims to provide a significant breakthrough in managing chronic cancer-related pain. The selection highlights the clinical relevance and potential of Autonomix's technology within the specialized medical community. For a small-cap medical device firm, such recognition at a major scientific conference provides essential clinical validation and increased visibility. Investors typically view these milestones as positive indicators of the company's progress toward broader commercial and regulatory acceptance.